Document is current
Any future updates will be listed below
-
Authors
Zekavat, Seyedeh M.
Viana-Huete, Vanesa https://orcid.org/0000-0001-8390-1346
Matesanz, Nuria https://orcid.org/0000-0002-5756-3424
Jorshery, Saman Doroodgar
Zuriaga, María A.
Uddin, Md Mesbah https://orcid.org/0000-0003-1846-0411
Trinder, Mark
Paruchuri, Kaavya https://orcid.org/0000-0003-1228-1674
Zorita, Virginia
Ferrer-Pérez, Alba https://orcid.org/0000-0002-9378-6115
Amorós-Pérez, Marta https://orcid.org/0000-0003-0025-0731
Kunderfranco, Paolo https://orcid.org/0000-0003-3636-3391
Carriero, Roberta
Greco, Carolina M.
Aroca-Crevillen, Alejandra
Hidalgo, Andrés
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Ballantyne, Christie M.
Niroula, Abhishek
Gibson, Christopher J.
Pirruccello, James
Griffin, Gabriel
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Libby, Peter https://orcid.org/0000-0002-1502-502X
Fuster, Valentín
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Ghassemi, Marzyeh
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Fuster, José J. https://orcid.org/0000-0002-5970-629X
Klarin, Derek https://orcid.org/0000-0002-4636-5780
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (1IK2BX005759-01)
- License Information
-
More Information
Article History
Received: 30 March 2022
Accepted: 8 December 2022
First Online: 16 January 2023
Competing interests
: D.K. is a scientific advisor for and accepts consulting fees from Bitterroot Bio. P.N. reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific and Novartis; spousal employment and equity at Vertex; consulting income from Apple, AstraZeneca, Novartis, Genentech/Roche, Blackstone Life Sciences, Foresite Labs and TenSixteen Bio; and is a scientific advisory board member and shareholder of TenSixteen Bio and geneXwell, all unrelated to this work. P.L. is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Novo Nordisk, Novartis, Pfizer and Sanofi-Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Moderna, Novartis, PlaqueTec, TenSixteen Bio, Soley Therapeutics, and XBiotech. P.L.ʼs laboratory has received research funding in the last 2 years from Novartis. P.L. is on the board of directors of XBiotech. P.L. also has a financial interest in Xbiotech, a company developing therapeutic human antibodies; in TenSixteen Bio, a company targeting somatic mosaicism and CHIP to discover and develop novel therapeutics to treat age-related diseases; and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. P.L.ʼs interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. B.L.E. is a member of the scientific advisory board and a shareholder for Neomorph, TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. A.G.B. is a paid advisor and holds equity in TenSixteen Bio. S.M.D. has received research support via the University of Pennsylvania from RenalytixAI and Novo Nordisk. The other authors do not have any competing interests.
